

# Absolute flow after successful PCI of a CTO.

## The FLOW-CTO study



Madrid Microcirculation  
Meeting - 4th Edition -



Hospital Universitario  
de La Princesa

Marcos García-Guimarães, PhD.

Interventional cardiologist.

Hospital Universitari Arnau de Vilanova, Lleida, Spain

Institut de Recerca Biomèdica de Lleida (IRBLleida)

 Hospital Universitari  
Arnau de Vilanova Lleida

 IRB<sup>L</sup>eida<sup>R</sup>  
Institut de Recerca Biomèdica

# Background

- ***Chronic total occlusion (CTO)*** causes abnormalities in the vascular bed distal to the lesion and related microvasculature.
- Percutaneous coronary intervention (PCI) of a CTO improves quality of life (QoL) and reduces angina.
- Positron emission tomography (PET) scans have shown improvement in myocardial blood flow and coronary flow reserve (CFR) after CTO PCI. Flow improvement is not immediate and can take weeks or months\*.
- ***Manual bolus thermodilution techniques*** → indirect methods for the estimation of coronary flow and resistance, like CFR and index of microcirculatory resistance (IMR) have inherent limitations and require adenosine.
  - Schumacher SP et al. Recovery of myocardial perfusion after percutaneous coronary intervention of chronic total occlusions is comparable to hemodynamically significant non-occlusive lesions. Catheter Cardiovasc Interv. 2019;93:1059-1066.

# Background

- **Continuous thermodilution method<sup>1</sup>** : allows quantification of absolute coronary blood flow (mL/min) and absolute microvascular resistance (Wood units) → more reproducible and adenosine-free.
- A previous study with short follow-up (control angiogram  $\leq$  2 months) showed some in absolute coronary blood flow and resistance after CTO PCI<sup>2</sup>.




**Objective:** To assess absolute coronary flow (and resistance) measured by continuous thermodilution immediately after PCI of a CTO and 6 months after the procedure.

1. Fournier S, et al. Normal values of thermodilution-derived absolute coronary blood flow and microvascular resistance in humans. *EuroIntervention*. 2021;17:e309-e316.
2. Keulards DCJ et al. Recovery of Absolute Coronary Blood Flow and Microvascular Resistance After Chronic Total Occlusion Percutaneous Coronary Intervention: An Exploratory Study. *J Am Heart Assoc*. 2020 May 5;9(9):e015669.

# Methods

## Inclusion criteria

- Patients with a clinical indication for PCI of a CTO in whom, a baseline study is performed after PCI and an angiographic follow-up at 6 months after the procedure.



Garcia-Guimaraes M, Gutierrez-Barrios A, Gomez-Lara J, et al. Microvascular dysfunction and invasive absolute coronary flow after percutaneous coronary intervention for a chronic total occlusion. The FLOW-CTO study. Rev Esp Cardiol (Engl Ed). 2022; 75:769-771.

# Functional assessment - determinations


## 1. PressureWire X (Abbott Vascular, Santa Clara, California)

- Hyperemia with adenosine (bolus thermodilution method)

- Fractional Flow Reserve (FFR)
- Index of Microcirculatory Resistance (IMR)
- Coronary flow reserve (CFR)




Madrid Microcirculation  
Meeting 4th Edition



$$\text{Absolute flow } (Q) = Q_i \frac{T_i}{T} 1.08$$

$$\text{Absolute resistance } (R) = \frac{P_d}{Q}$$

Wire with distal pressure/temperature sensor to measure distal coronary temperature ( $T$ ), then pullback into the infusion catheter to measure the infusion temperature ( $T_i$ )



## 2. RayFlow (Hexacath, Paris, France)

- Absolute Flow (mL/min)
- Resistance (Woods units)

## 3. Measurements were analyzed with Coroventis (Coroflow, Uppsala, Sweden).

# Results – flow chart

4 Spanish centers with broad experience in CTO PCI and coronary physiology:

- Hospital del Mar, Barcelona
- Hospital Universitari de Bellvitge, Barcelona
- Hospital Puerta del Mar, Cádiz
- Hospital de La Princesa, Madrid



Microcirculation  
Meeting - 4th Edition -

Jan 2021- Jan 2022

49 patients

49 patients  
Baseline  
measurements

9 patients declined 6-month follow-up angiography

40 patients  
6-month control  
angiogram

39 patients  
(39 lesions)  
FFR measurement

40 patients  
(42 lesions)  
AF measurement

32 patients  
(32 lesions)  
CFR/IMR  
measurement

# Results - background

	N=40
Sex (male)	36 (90)
Age (years)	63 [55-69]
Height (cm)	171 [169-174]
Weight (kg)	79 [73-88]
BMI ( $\text{kg}/\text{m}^2$ )	27 [25-29]
Overweight (BMI $\geq 25$ )	30 (75)
Obesity (BMI $\geq 30$ )	9 (23)
Systemic hypertension	29 (73)
Hyperlipidemia	27 (68)
Diabetes mellitus	15 (38)
Insulin dependent DM	6/15 (40)
Smoking habit	
Never	18 (45)
Ex-smoker	10 (25)
Current habit	12 (30)
Peripheral arterial disease	4 (10)
Family history IHD	5 (13)
CKD (eGFR $< 60 \text{ ml/min/m}^2$ )	5 (13)

	N=40
Previous IHD	24 (60)
Previous MI	14 (35)
MI location	
Anterior	3/14 (21)
Inferior	6/14 (43)
Lateral	2/14 (14)
Undetermined	3/14 (21)
Previous PCI	21 (53)
Previous CABG	2 (5)
LVEF (%)	55 [45-61]
LV systolic dysfunction (LVEF $< 40\%$ )	6 (15)
Anginal symptoms	36 (90)
Angina CCS class	
I	4 (11)
II	28 (78)
III	4 (11)
IV	0
Previous HF	5 (13)
HF NYHA class	
I	0
II	4 (80)
III	1 (20)
IV	0

# Results - background



	N=40
<b>Ischemia/viability test</b>	23 (58)
<b>Type of ischemia/viability test</b>	
Stress echocardiogram	5 (22)
SPECT/PET	9 (39)
cMR	9 (39)
<b>Inducible ischemia</b>	23 (58)
<b>Viability</b>	40 (100)
<b>Aspirin</b>	36 (90)
<b>    Clopidogrel</b>	8 (20)
<b>    Ticagrelor</b>	18 (45)
<b>Prasugrel</b>	2 (5)
<b>DAPT</b>	26 (65)
<b>Oral anticoagulation</b>	2 (5)
<b>Beta-blockers</b>	36 (90)
<b>ACEi-ARBs</b>	33 (83)
<b>Statins</b>	38 (95)
<b>Calcium channel blocker</b>	6 (15)
<b>Nitrates</b>	11 (28)
<b>Ranolazine</b>	5 (13)
<b>Ivabradine</b>	1 (3)
<b>Trimetazidine</b>	1 (3)

MacLeod Microcirculation  
Meeting 4th Edition -

Hospital Universitario  
de La Princesa  
SaludMadrid

# Results – CTO characteristics

	N=42
CTO vessel	
LAD	11 (26)
LCX	7 (17)
RCA	24 (57)
Main collateral vessel	
LAD	26 (62)
LCX	5 (12)
RCA	11 (26)
Bridge collaterals	15 (36)
Retrograde filling	42 (100)

Madrid Microcirculation  
Meeting - 4th Edition -

	N=42
Collateral size (Werner)	
0	2 (5)
1	17 (40)
2	23 (55)
Rentrop classification	
0	0
1	6 (14)
2	13 (31)
3	23 (55)
J-CTO tapered blunt	24 (57)
J-CTO calcification	16 (38)
J-CTO bending	12 (29)
J-CTO length	18 (43)
J-CTO retry	5 (12)
J-CTO total score	
0	4 (9.5)
1	15 (36)
2	11 (26)
3	11 (26)
4	1 (2.4)

# Results – CTO PCI

	N=42
<b>Antegrade access</b>	
Radial	2 (5)
<b>Femoral</b>	<b>39 (93)</b>
Ulnar	1 (2)
Brachial	0
<b>Retrograde access</b>	
Radial	20 (48)
Femoral	20 (48)
Ulnar	0
Brachial	2 (5)
<b>Antegrade guiding size (French)</b>	
6 F	5 (12)
7 F	25 (59)
8 F	12 (29)

	N=42
<b>CTO technique</b>	
AWE	30 (71)
RWE	7 (17)
ADR	5 (12)
RDR	0
<b>Amount of contrast (mL)</b>	267 [205-345]
<b>Procedural time (min)</b>	116 [90-155]
<b>Fluoroscopy time (min)</b>	37 [29-45]
<b>Total number of stents implanted</b>	2 [1-3]
<b>Total stent length (mm)</b>	60 [41-76]
<b>Maximal stent diameter</b>	3.26 ± 0.4
<b>Minimal stent diameter</b>	2.7 ± 0.4
<b>Final TIMI flow</b>	
0	0
1	0
2	2 (5)
<b>3</b>	<b>40 (95)</b>
<b>QCA analysis post-PCI (in-segment)</b>	
<b>Minimal diameter (mm)</b>	1.9 ± 0.5
<b>Maximal diameter (mm)</b>	3.8 ± 0.8
<b>Mean diameter (mm)</b>	2.9 ± 0.5
<b>Minimal area (mm<sup>2</sup>)</b>	3.0 ± 1.5
<b>Segment length (mm)</b>	64 [49-76]
<b>% Diameter stenosis (DS)</b>	28 ± 10
<b>CAAS vFFR</b>	0.89 [0.85-0.94]

# Results – coronary physiology immediately after CTO PCI



Madrid Microcirculation Meeting - 4th Edition - Hospital Universitario de La Princesa

	N=42
FFR	0.89 [0.82-0.94]
FFR ≤ 0.80	9 (21)
CFR	2.0 [1.4-2.5]
IMR	13 [8-21]
MVD (CFR<2.0 ± IMR ≥25)	24 (57)
AF Q (mL/min)	188 [127-240]
AF Qnorm (mL/min)	197 [138-263]
R (WU)	451 [315-625]

# Results – 6 months control angiogram





	N=42
Time to follow-up (months)	6 [5-8]
QCA analysis post-PCI (in-segment)	
Minimal diameter (mm)	1.9 ± 0.5
Maximal diameter (mm)	3.5 ± 0.7
Mean diameter (mm)	2.7 ± 0.4
Minimal area (mm <sup>2</sup> )	3.1 ± 1.3
% Diameter stenosis (DS)	24 ± 12
Binary restenosis	6 (14)
CAAS vFFR	0.89 [0.82-0.94]
Coronary physiology	
FFR	0.87 [0.82-0.92]
FFR ≤ 0.80	7/39 (18)
CFR	2.75 [1.6-3.6]
IMR	13 [10-24]
MVD (CFR<2.0 ± IMR ≥25)	1/32 (3)
AF Q (mL/min)	214 [149-277]
AF Qnorm (mL/min)	236 [172-300]
R (WU)	349 [287-433]

# Results – baseline vs follow-up





	Baseline	Follow-up	p-paired
FFR	0.88 ± 0.08	0.85 ± 0.10	0.0820
CFR	1.99 ± 0.9	2.7 ± 1.3	0.0086
IMR	15 ± 9	13 ± 8	0.2543
MVD (CFR<2.0 & IMR≥25)	18/32 (56)	1/32 (3)	<0.001
AF Q (mL/min)	187 ± 68	223 ± 95	0.0077
AF Qnorm (mL/min)	208 ± 87	262 ± 130	0.0081
R (WU)	474 ± 203	368 ± 140	0.0004

# Results – Absolute flow



67% lesions AF increased  
Mean change 19% increase



# Results – Resistance



71% lesions R decreased  
Mean change 29% decrease

# Results – Coronary Flow Reserve

Coronary Flow Reserve (CFR)



78% lesions CFR increased  
Mean change 36% increase

# Conclusions

1. A significant percentage of patients (57%) undergoing PCI of a CTO have criteria of MVD (based on CFR and IMR) immediately after coronary artery recanalization. This percentage is markedly reduced at 6 months follow-up.
2. We observed a significant increase in the CFR values (by 39%) at 6-month follow-up versus baseline.
3. Using the continuous thermodilution method, we observed a significant increase in absolute coronary flow (by 19%), accompanied by a decrease in microvascular resistance (by 29%) at 6-month follow-up.
4. Further studies are needed to assess the relationship between changes observed during follow-up in flow and resistance profile and improvement in symptoms and myocardial function after CTO PCI.

Thank You for your  
attention.

Any questions?

(this is the part where

you run)

Madrid Microcirculation  
Meeting - 4th Edition -

